Teva Pharmaceutical Industries Ltd. (TEVJF)
Market Open
6 Jun, 20:00
OTC PINK OTC PINK Primary $
17. 80
0
0%
$
17.85B Market Cap
- P/E Ratio
0% Div Yield
0 Volume
0 Eps
$ 17.8
Previous Close Day Range
17.8 17.8
Year Range
13.73 22.91
Earnings results expected in 50 days
Summary
TEVJF trading today higher at $17.8, an increase of 0% from yesterday's close, completing a monthly increase of 28.99% or $4. Over the past 12 months, TEVJF stock lost -3.78%.
TEVJF pays dividends to its shareholders, with the most recent payment made on Dec 02, 2013. The next estimated payment will be in 2 Mar 2014 on Mar 02, 2014 for a total of $1.15.
The last earnings report, released on May 07, 2025, exceeded the consensus estimates by 0.18%. On average, the company has surpassed earnings expectations by 0.06%, based on the last three reports. The next scheduled earnings report is due on Jul 29, 2025.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).
Want to track TEVJF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
TEVJF Chart
Teva Pharmaceutical Industries Ltd. Dividends
| TEVJF 28 Nov 2017 | Other | $0.09 Per Share |
| TEVJF 29 Aug 2017 | Other | $0.09 Per Share |
| TEVJF 5 Jun 2017 | Other | $0.34 Per Share |
| TEVJF 2 Mar 2017 | Other | $0.34 Per Share |
| TEVJF 5 Dec 2016 | Other | $0.34 Per Share |
Teva Pharmaceutical Industries Ltd. Earnings
| 29 Jul 2025 (50 Days) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | 0.18 EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 29 Jan 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| TEVJF 28 Nov 2017 | Other | $0.09 Per Share |
| TEVJF 29 Aug 2017 | Other | $0.09 Per Share |
| TEVJF 5 Jun 2017 | Other | $0.34 Per Share |
| TEVJF 2 Mar 2017 | Other | $0.34 Per Share |
| TEVJF 5 Dec 2016 | Other | $0.34 Per Share |
| 29 Jul 2025 (50 Days) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | 0.18 EPS |
| 6 May 2025 Date | | - Cons. EPS | - EPS |
| 29 Jan 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
Teva Pharmaceutical Industries Ltd. (TEVJF) FAQ
What is the stock price today?
The current price is $17.80.
On which exchange is it traded?
Teva Pharmaceutical Industries Ltd. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is TEVJF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 17.85B.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Jul 29, 2025.
Has Teva Pharmaceutical Industries Ltd. ever had a stock split?
No, there has never been a stock split.
Teva Pharmaceutical Industries Ltd. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Richard D. Francis CEO | OTC PINK Exchange | IL0006290147 ISIN |
| IL Country | 37,000 Employees | 11 Nov 2010 Last Dividend | 11 Dec 2002 Last Split | - IPO Date |
Overview
Teva Pharmaceutical Industries Limited is a global leader in the development, manufacturing, marketing, and distribution of both generic and specialty medicines, as well as biopharmaceutical products. With operations spanning North America, Europe, Israel, and internationally, Teva focuses on providing a wide range of health solutions. The company is known for its extensive portfolio which includes various dosage forms like tablets, capsules, injectables, and more, tailored to treat a vast spectrum of conditions. Teva dedicates significant efforts to areas such as the central nervous system (CNS), respiratory, and oncology, aiming to advance healthcare and improve the quality of life for patients around the world. Established in 1901 and headquartered in Tel Aviv, Israel, Teva also engages in the production of active pharmaceutical ingredients and offers contract manufacturing services, supporting other entities in the pharmaceutical industry through an out-licensing platform.
Products and Services
- Generic Medicines: Teva provides a comprehensive range of generic medicines, encompassing various dosage forms like tablets, injectables, and more, catering to a myriad of health conditions.
- Specialty Medicines: The company's specialty medicine segment includes products for the treatment of conditions in CNS, respiratory diseases, and oncology. Notable offerings include:
- BENDEKA/TREANDA: Injections used for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
- COPAXONE: For relapsing forms of multiple sclerosis.
- AJOVY: Preventive treatment for migraine in adults.
- AUSTEDO: Addresses neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia.
- UZEDY: For the treatment of schizophrenia.
- Biopharmaceutical Products: Includes products like GRANIX, TRISENOX, LONQUEX, and TEVAGRASTIM/RATIOGRASTIM, among others, focusing on advanced therapies.
- Respiratory Products: A range of products designed for asthma and other respiratory conditions, including ProAir RespiClick, QVAR, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick.
- OTC Products: Teva offers over-the-counter products under brand names such as SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA, providing accessible health solutions.
- Active Pharmaceutical Ingredients (APIs) and Contract Manufacturing: The company provides APIs and offers contract manufacturing services, showing its versatility in the pharmaceutical industry.
- Collaborations and Licenses: Teva has entered into collaboration agreements with companies like MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., and holds a license agreement with MODAG GmbH. These partnerships enrich its product offerings and enhance its R&D capabilities.
Contact Information
Address: 124 Dvora Hanevi’a Street
Phone: 972 3 914 8213
Website: https://www.tevapharm.com
2025 © Marketlog. All Rights Reserved.
